|
JP2938527B2
(ja)
*
|
1990-07-30 |
1999-08-23 |
株式会社リコー |
自動原稿給送装置
|
|
DK2242771T3
(da)
*
|
2007-12-14 |
2013-08-26 |
Pfizer |
Bindingsmolekyler til den humane ox40-receptor
|
|
SG2014014708A
(en)
|
2009-02-17 |
2014-05-29 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
|
US20120020960A1
(en)
*
|
2010-07-26 |
2012-01-26 |
Baylor Research Institute |
Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
|
|
AP2013006771A0
(en)
|
2010-08-23 |
2013-03-31 |
Boards Of Regents The University Of Texas System |
Anti-OX40 antibodies and methods of using the same
|
|
WO2013028231A1
(en)
*
|
2011-08-23 |
2013-02-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
SI2614082T1
(sl)
|
2010-09-09 |
2018-12-31 |
Pfizer Inc. |
Molekule, ki vežejo 4-1BB
|
|
CA3158257A1
(en)
*
|
2011-07-11 |
2013-01-17 |
Ichnos Sciences SA |
Antibodies that bind to ox40 and their uses
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
AU2013306390B2
(en)
|
2012-08-24 |
2018-07-05 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
DK2925350T3
(da)
|
2012-12-03 |
2019-05-13 |
Bristol Myers Squibb Co |
Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
|
|
DK2976361T3
(da)
|
2013-03-18 |
2018-10-01 |
Biocerox Prod Bv |
Humaniserede anti-cd134- (0x40) antistoffer og anvendelser deraf
|
|
HRP20231437T1
(hr)
|
2013-08-08 |
2024-02-16 |
Cytune Pharma |
Il-15 i il-15ralpha sushi domena na temelju modulokina
|
|
JP2017501167A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
|
|
KR102127408B1
(ko)
*
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
CN106103486B
(zh)
*
|
2014-03-31 |
2020-04-21 |
豪夫迈·罗氏有限公司 |
抗ox40抗体和使用方法
|
|
CA2943834A1
(en)
*
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
TWI733652B
(zh)
|
2014-07-11 |
2021-07-21 |
美商基利科學股份有限公司 |
用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
|
|
TW201619200A
(zh)
*
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
|
RU2017119231A
(ru)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
|
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
|
KR20170096112A
(ko)
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
|
SMT201900702T1
(it)
*
|
2015-01-08 |
2020-01-14 |
Genmab As |
Agenti agonistici leganti il recettore del tnf
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
CN112263677A
(zh)
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
|
EA201792451A1
(ru)
*
|
2015-05-07 |
2018-05-31 |
Агенус Инк. |
Антитела к ox40 и способы их применения
|
|
CN114181309B
(zh)
*
|
2015-05-21 |
2024-07-30 |
鳄鱼生物科学公司 |
新型多肽
|
|
GB201509338D0
(en)
*
|
2015-05-29 |
2015-07-15 |
Bergenbio As |
Combination therapy
|
|
WO2016196228A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
|
EP3310810A1
(en)
|
2015-06-16 |
2018-04-25 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
EP3112381A1
(en)
*
|
2015-07-01 |
2017-01-04 |
FONDAZIONE IRCCS Istituto Nazionale dei Tumori |
Bispecific antibodies for use in cancer immunotherapy
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
MX2018003820A
(es)
|
2015-10-02 |
2018-12-10 |
F Hoffmann La Roche Ag |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
|
|
JP6771551B2
(ja)
*
|
2015-10-15 |
2020-10-21 |
ディンフー バイオターゲット カンパニー リミテッド |
抗ｏｘ４０抗体及びその応用
|
|
JP2019500893A
(ja)
|
2015-11-03 |
2019-01-17 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
|
|
EP4015537A1
(en)
|
2015-12-01 |
2022-06-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods for using them
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
CN108473587A
(zh)
*
|
2016-01-25 |
2018-08-31 |
辉瑞公司 |
用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
IL295649B2
(en)
|
2016-04-07 |
2025-12-01 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
BR112018072740A2
(pt)
|
2016-05-05 |
2019-02-19 |
Glaxosmithkline Intellectual Property (No. |
realçador de inibidores de homólogo 2 de zeste
|
|
ES3010640T3
(en)
|
2016-06-20 |
2025-04-04 |
Invox Pharma Ltd |
Lag-3 binding members
|
|
CN109996544A
(zh)
|
2016-06-27 |
2019-07-09 |
加利福尼亚大学董事会 |
癌症治疗组合
|
|
AU2017298535B2
(en)
*
|
2016-07-19 |
2020-12-10 |
Ibentrus, Inc. |
Bispecific proteins and methods for preparing same
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
EP3487503A1
(en)
|
2016-07-20 |
2019-05-29 |
GlaxoSmithKline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
CA3033661A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
KR102124286B1
(ko)
*
|
2016-09-07 |
2020-06-18 |
삭신 라이프사이언스 피브이티 엘티디 |
Vegf에 대한 합성 항체 및 이들의 용도
|
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CA3045241A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
EP3548068A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
US10556962B2
(en)
|
2016-12-15 |
2020-02-11 |
Abbvie Biotherapeutics Inc. |
Anti-OX40 antibodies and their uses
|
|
AU2017384528A1
(en)
|
2016-12-19 |
2019-07-04 |
Ichnos Sciences SA |
Novel TNFR agonists and uses thereof
|
|
EP4467565A3
(en)
|
2016-12-21 |
2025-03-12 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
WO2018129332A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
CN110573504A
(zh)
|
2017-02-27 |
2019-12-13 |
葛兰素史克知识产权开发有限公司 |
作为激酶抑制剂的杂环酰胺
|
|
CN108623686A
(zh)
*
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
WO2018226714A1
(en)
|
2017-06-05 |
2018-12-13 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
WO2018225034A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
CA3066007A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
EP3672634A1
(en)
*
|
2017-08-24 |
2020-07-01 |
Invenra, Inc. |
Multivalent receptor-clustering agonist antibody constructs
|
|
US10363272B2
(en)
*
|
2017-08-31 |
2019-07-30 |
Io Therapeutics, Inc. |
RAR selective agonists in combination with immune modulators for cancer immunotherapy
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
EP3692033A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
|
JP7291130B2
(ja)
|
2017-10-05 |
2023-06-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
DK3710576T3
(da)
|
2017-11-17 |
2025-01-02 |
Iovance Biotherapeutics Inc |
Til-ekspansion fra finnålsaspirater og små biopsier
|
|
AU2017440393B2
(en)
*
|
2017-11-24 |
2025-02-20 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-OX40 antibodies and uses thereof
|
|
US11142579B2
(en)
|
2017-12-06 |
2021-10-12 |
Sorrento Therapeutics, Inc. |
Variant antibodies that bind OX40
|
|
KR102452246B1
(ko)
*
|
2017-12-29 |
2022-10-12 |
에이피 바이오사이언시스, 아이엔씨. |
암 치료법을 위한 면역 체크포인트 조절을 갖는 단일특이성 및 이중특이성 단백질
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
SG11202006541UA
(en)
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
AU2019264712A1
(en)
*
|
2018-05-11 |
2021-01-07 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Fully human antibodies against OX40, method for preparing same, and use thereof
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
BR112020022897A2
(pt)
|
2018-05-23 |
2021-02-23 |
Pfizer Inc. |
anticorpos específicos para cd3 e usos dos mesmos
|
|
KR102584675B1
(ko)
|
2018-05-23 |
2023-10-05 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
SG11202100172XA
(en)
|
2018-07-12 |
2021-02-25 |
F Star Beta Ltd |
Antibody molecules that bind cd137 and ox40
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
CN112423845B
(zh)
|
2018-07-12 |
2024-07-30 |
F-星治疗有限公司 |
结合pd-l1和cd137的抗体分子
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
WO2020061429A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
US12343380B2
(en)
|
2018-11-05 |
2025-07-01 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs utilizing AKT pathways inhibitors
|
|
MX2021004953A
(es)
|
2018-11-05 |
2021-08-11 |
Iovance Biotherapeutics Inc |
Seleccion de celulas t reactivas al tumor mejoradas.
|
|
CN113272421B
(zh)
|
2018-11-05 |
2025-02-18 |
艾欧凡斯生物治疗公司 |
用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
|
|
SG11202104663PA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
CA3118542A1
(en)
|
2018-11-09 |
2020-05-14 |
Beth Israel Deaconess Medical Center |
Cdcp1-targeted therapies
|
|
JP7710372B2
(ja)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
|
BR112021014911A2
(pt)
|
2019-02-01 |
2021-11-23 |
Glaxosmithkline Ip Dev Ltd |
Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2022533833A
(ja)
|
2019-05-24 |
2022-07-26 |
ファイザー・インク |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
|
CN110172090B
(zh)
*
|
2019-06-03 |
2020-04-03 |
中山标佳生物科技有限公司 |
Cd134单克隆抗体及其制备方法和癌症治疗中的应用
|
|
US20230295313A1
(en)
|
2019-06-26 |
2023-09-21 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
AU2020355614B2
(en)
|
2019-09-27 |
2024-12-05 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
AU2020391231A1
(en)
|
2019-11-27 |
2022-07-14 |
Turnstone Biologics Corp. |
Method of producing tumor-reactive T cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
|
US20230043985A1
(en)
|
2019-12-18 |
2023-02-09 |
Pfizer Inc. |
Once daily cancer treatment regimen with a prmt5 inhibitor
|
|
JP7662644B2
(ja)
|
2019-12-18 |
2025-04-15 |
シーティーエックスティー・ピーティーワイ・リミテッド |
化合物
|
|
BR112022014562A2
(pt)
|
2020-01-28 |
2022-09-13 |
Glaxosmithkline Ip Dev Ltd |
Tratamentos de combinação, usos e métodos dos mesmos
|
|
KR20220158727A
(ko)
|
2020-02-27 |
2022-12-01 |
미스트 쎄라퓨틱스, 엘엘씨 |
종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
|
|
CA3174908A1
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
WO2021190431A1
(zh)
|
2020-03-23 |
2021-09-30 |
百奥泰生物制药股份有限公司 |
一种免疫细胞激活剂的开发及应用
|
|
WO2021191865A1
(en)
*
|
2020-03-26 |
2021-09-30 |
Dusa Pharmaceuticals, Inc. |
Management of dermal neurofibromatosis lesions
|
|
KR20230015328A
(ko)
|
2020-04-17 |
2023-01-31 |
허치슨 메디파르마 리미티드 |
항-ox40 항체 및 이의 용도
|
|
EP4146794A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
|
EP4149975A2
(en)
|
2020-05-13 |
2023-03-22 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
JP2023525085A
(ja)
|
2020-05-13 |
2023-06-14 |
アダジーン アーゲー |
がんを治療するための組成物および方法
|
|
WO2022013775A1
(en)
|
2020-07-17 |
2022-01-20 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
|
CA3194925A1
(en)
|
2020-09-14 |
2022-03-17 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CN114515335A
(zh)
|
2020-11-19 |
2022-05-20 |
百奥泰生物制药股份有限公司 |
抗ox40抗体在治疗肿瘤或癌症中的应用
|
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
US20240131064A1
(en)
|
2020-12-11 |
2024-04-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
WO2022153161A1
(en)
|
2021-01-14 |
2022-07-21 |
Pfizer Inc. |
Treatment of cancer using a prmt5 inhibitor
|
|
US20240299540A1
(en)
|
2021-02-05 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
JP2024509529A
(ja)
|
2021-03-02 |
2024-03-04 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Ｄｎｍｔ１阻害剤としての置換ピリジン
|
|
WO2022198055A1
(en)
*
|
2021-03-19 |
2022-09-22 |
KSQ Therapeutics, Inc. |
Uses of antagonist, non-depleting ox40 antibodies
|
|
US20240166747A1
(en)
|
2021-03-31 |
2024-05-23 |
Glazosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
AU2022228085A1
(en)
|
2021-09-07 |
2023-03-23 |
Joy Global Underground Mining Llc |
Support for drilling and bolting tool
|
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
EP4448578A4
(en)
|
2021-12-17 |
2026-02-18 |
Shanghai Henlius Biotech Inc |
ANTI-OX40 ANTIBODIES, MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
|
|
JP2025503987A
(ja)
|
2022-01-28 |
2025-02-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
ペイロードを発現するように操作された腫瘍浸潤リンパ球
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
|
EP4540278A1
(en)
|
2022-06-17 |
2025-04-23 |
Pfizer Inc. |
Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
|
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
PE20250259A1
(es)
|
2022-07-05 |
2025-01-29 |
Pfizer |
Compuestos de pirido[4,3-d] pirimidina
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024074977A1
(en)
|
2022-10-04 |
2024-04-11 |
Pfizer Inc. |
Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
|
|
CN120379671A
(zh)
|
2022-10-18 |
2025-07-25 |
辉瑞公司 |
用于治疗癌症的化合物
|
|
WO2024105563A1
(en)
|
2022-11-16 |
2024-05-23 |
Pfizer Inc. |
Substituted bicyclic pyridone derivatives
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
CR20250413A
(es)
|
2023-04-05 |
2025-11-06 |
Pfizer |
Compuestos de pirido[4,3–d]pirimidina
|
|
WO2024213979A1
(en)
|
2023-04-10 |
2024-10-17 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024218686A1
(en)
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
AU2024271605A1
(en)
|
2023-05-12 |
2025-11-13 |
BioNTech SE |
Antibodies capable of binding to ox40, variants thereof and uses thereof
|
|
WO2025032521A1
(en)
|
2023-08-10 |
2025-02-13 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
WO2025094035A1
(en)
|
2023-11-01 |
2025-05-08 |
Pfizer Inc. |
Toll-like receptor agonists and conjugates thereof
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|